AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER ...

THOUSAND OAKS, Calif., and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (AMGN) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today announced new results from the ongoing ROCKET Phase 3 clinical ...

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics.

THOUSAND OAKS, Calif., Feb. 28, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the 45 th Annual TD Cowen Health Care Conference at 9:10 a.m. ET on Wednesday, March 5, 2025. Jay Bradner ...

Amgen is also dipping its toes in the fast-growing weight loss market -- arguably the hottest therapeutic area in the industry. Its most advanced candidate, MariTide, is in a phase 2 study.

Amgen's Karol Speight discusses the trends dictating careers in the forensic analysis and wider biopharma industries.

Amgen, based in Thousand Oaks, California, first broke ground in New Albany in 2021. Here's how the company plans to expand.

In the long-running feud between Regeneron and Amgen around the companies’ competing PCSK9 cholesterol meds, Regeneron has eked out another legal win.

A Delaware federal trial jury found Thousand Oaks, California-based drug company Amgen Inc. liable Thursday for federal and state antitrust violations amounting to more than $400 million in damages.

Why PR Is Your Brand’s Best Defense in the AI Search Era Be proactive in getting your company’s name and reputation established for more than just traditional search engines.

Amgen sees a significant opportunity in international markets. Management thinks these launches abroad will start impacting revenue growth next year.